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Abstract 16 
Epigenetic and chromatin modifications have important roles in governing gene activity and 17 
nuclear architecture. They are also necessary for normal embryonic development and cell 18 
differentiation. Early epigenetic programming events during mouse embryogenesis are believed 19 
to be essential for normal growth and development. Aberrant epigenetic profiles are associated 20 
2 
with the conversion of normal cell phenotypes into cancer cells. Because epigenetic alterations 21 
are potentially reversible, experimental progress in this area may offer great promise for new 22 
cancer therapy. Nuclear epigenetic profiles can be manipulated using techniques such as somatic 23 
cell reprogramming, genetic engineering and small molecules, which can reprogramme the cell 24 
towards dedifferentiation and transdifferentiation. Advances into the mechanisms will improve 25 
the potential for regenerative medicine. In this review, we describe the principles of epigenetics 26 
and its relation to cell reprogramming, differentiation, dedifferentiation and transdifferentiation. 27 
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Review methodology 31 
Literature was sourced from PubMed, Google Scholar and Web of Science; journal publishers; 32 
meeting reports and communications from colleagues. In addition to these articles, we checked 33 
references cited by the authors for additional relevant material.  34 
 35 
Epigenetic definitions 36 
Epigenetics describes the phenomena between genotype and phenotype that can alter the 37 
phenotypic outcome associated with genomic loci in the absence of changes to the underlying 38 
DNA sequence [1]. For example, the majority of cells in our body share an identical genotype 39 
originally derived from the first single cell after fertilisation, the zygote, yet these cells can have 40 
different morphologies and functions. During development, cells eventually generate a diversity 41 
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of disparate and stable cell types in a process called cellular differentiation. These transitions 42 
were first envisioned by Waddington as being governed by changes in trajectory across a 43 
conceptual ‘epigenetic landscape’, rather than by alterations in genetic inheritance [2]. In 44 
molecular terms, epigenetics is defined as the study of any potentially stable and heritable 45 
change in gene expression or cellular phenotype that occurs without altering the DNA sequence 46 
of the cell lineage [1]. The mechanisms can involve covalent modification marks on histones and 47 
DNA or non-coding RNAs (ncRNAs) [3-5]. ncRNAs are transcribed from DNA but are not 48 
translated into proteins; those ncRNAs that appear to be involved in epigenetic processes [6] can 49 
mediate non-mendelian inheritance of an epigenetic change [7].  50 
Epigenetic modifications include the methylation states of cytosine residues of DNA and 51 
posttranslational methylation groups on the histone proteins associated with the DNA.  Co-52 
regulator proteins with binding domains for these chemical groups may associate with these 53 
epigenetic marks and affect the activity of nearby genes [8, 9]. The specific combination of 54 
epigenetic modifications may furthermore determine the conformation of the chromatin fibre 55 
into which the DNA and histones are packaged, and can thereby regulate the transcriptional 56 
potential of the underlying genes [4, 10]. This is based on the notion that repression of gene 57 
expression is caused by a lack of accessibility to the gene by the RNA polymerase [11], as well 58 
as its recruitment [12].  59 
During development as well as in adult life, an interplay exists between the environment and 60 
genome; however, the currently known framework of gene–environment interactions is not 61 
sufficient to fully explain the risks of common diseases, some of which appear modulated by 62 
epigenetic mechanisms [13]. Many environmental factors have been implicated in aberrant 63 
epigenetic changes both in experimental and epidemiological studies [14]. These environmental 64 
epigenetic modulators include nutrients, oxygen, temperature, radiation, pollution, chemicals and 65 
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toxins [13-17]. Specific epigenetic modifications and transcriptional profiles have been shown to 66 
have a dynamic potential for rapidly adapting to culture conditions [17, 18] 67 
DNA methylation  68 
DNA methylation involves the addition of a methyl group to CpG sequences at the 5’ position of 69 
the cytosine ring (5-methylcytosine; 5mC). This modification, which occurs in the DNA of most 70 
but not all eukaryotes, is catalysed by DNA methyltransferases (Dnmt) and is generally 71 
associated with gene repression [3, 9, 11]. The repression mechanisms can act through direct 72 
interference by the methyl group or involve a family of methyl binding proteins and associated 73 
complexes in vertebrates [9]. DNA methylation can occur in two ways: de novo methylation 74 
relies on Dnmt3a and Dnmt3b enzymes that add new methyl groups to CpG sequences; whereas 75 
methylation maintenance requires Dnmt1 to restore methyl groups to hemi‐methylated CpG 76 
sequences following DNA replication [3, 12]. DNA methylation can be further modified, as part 77 
of a presumed active demethylation mechanism, by the Tet family of enzymes converting 5mC 78 
to 5-hydroxymethylcytosine (5hmC) and its higher oxidative products 5-formylcytosine (5fC) 79 
and 5-carboxylcytosine (5caC) [19-21]. 80 
Histone methylation 81 
Post-translational modifications can be found on the histone protein globular core regions, 82 
around which DNA is wrapped [22]. However, the majority of histone modifications occur on 83 
the lysine-rich N-terminal amino acid “tails” extending from the nucleosome structure [8]. These 84 
include: acetylation, phosphorylation, sumoylation, ubiquitination and methylation [23]. 85 
Methylation of histones is an epigenetically heritable histone modification found on lysine (K) or 86 
arginine (R) residues, produced by a family of histone methyltransferases (HMTs). Conversely, 87 
histone demethylases work to remove methyl groups from these residues [8]. Histone lysine 88 
residues can be mono- (me), di- (me2), or tri-methylated (me3); each of these posttranslational 89 
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modifications can have a decisive influence on gene and chromatin functions [24]. For instance, 90 
H3K9me3 represses gene transcription and assists in the formation of constitutive 91 
heterochromatin, while H3K9me2 represses genes in euchromatin as well as forming facultative 92 
heterochromatin [25]. Modifications of histone lysine can act as either repressive or active 93 
marks. For example, methylations of H3K4, H3K36 and H3K79 have been highly correlated 94 
with transcriptional activation, whereas methylations of H3K9, H3K27 and H4K20 are 95 
associated with repressive chromatin states [26, 27]. The repression mechanisms typically 96 
involve protein complexes with binding modules for these methyl groups [8]. This has led to a 97 
model describing the proteins involved in histone modification management as ‘writers, erasers 98 
and readers’, in an analogy with other signalling pathways [28]. 99 
Methylation of histone arginine residues by arginine methyltransferases (PRMTs) is less 100 
extensively studied but it has been found to play significant roles in gene regulation, 101 
development and cancer [29]. Histone arginine methylation can be transcriptionally activating 102 
[30] or repressive [31] depending on the target residue, and on whether the methylation is 103 
symmetric or asymmetric. In mammals, PRMT1- and CARM1-catalysed histone asymmetric 104 
histone dimethylation at arginine is involved in gene activation [30] while PRMT5-catalyzed 105 
symmetric histone dimethylated arginine is associated with gene repression [31]. 106 
Epigenetics and differentiation. 107 
In developmental biology, cellular differentiation is the process by which a less specialized cell 108 
(stem cell or progenitor) becomes a more specialized cell type. Differentiation can dramatically 109 
change a cell's morphology and function, as a result of alterations in gene expression with the 110 
involvement of epigenetic modifications [32, 33]. Differentiation occurs numerous times during 111 
development and continues into adulthood, as adult stem cells divide and create fully 112 
differentiated daughter cells during tissue repair and during normal cell turnover [34]. In cancer, 113 
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the differentiation state (sometimes referred as redifferentiation) is used in grading tumours to 114 
assess cancer progression, by comparing the genotype and phenotype of cancer tissue to normal 115 
tissue. Well-differentiated cancer cells are comparable to normal cells, in that they grow and 116 
spread more slowly than poorly differentiated or undifferentiated cancer cells [35, 36].  117 
Each cell population is thought to have its own characteristic epigenetic signature, which 118 
correlates with its differentiation potential. Mammalian development is a unidirectional process 119 
during which there is a progressive loss of developmental potential. It begins with the formation 120 
of a unicellular zygote and ends with the establishment of more than 200 specialized cell types of 121 
the mammalian body [37]. According to this diminishing differentiation potential, specific terms 122 
have been assigned to the individual cell populations that arise during development, such as: 123 
totipotency (ability to differentiate into intraembryonic tissue and extraembryonic tissue), 124 
pluripotency (ability to differentiate into intraembryonic tissue; ectoderm, mesoderm and 125 
endoderm), multipotency (ability to differentiate into two or more lineages) and unipotency 126 
(ability to differentiate to one lineage).  127 
It is thought that at specific stages in development and differentiation, biologically important 128 
differences in the ‘openness’ of chromatin occur. For example, chromatin in preimplantation 129 
embryos is more open than in postimplantation cells, while stem cell chromatin is less compact 130 
and more transcription-permissive than that of differentiated cells [18, 38]. Open chromatin 131 
structure, characterized by relatively few condensed heterochromatin areas, has a higher 132 
proportion of active epigenetic marks (i.e., H3K4me3, H3K39me and H3K79me) compared to 133 
repressive epigenetic marks (i.e., H3K9me, H4K20me and DNA methylation) [39]. In addition, 134 
developmental genes can be ‘bivalent’, marked by both the active epigenetic mark H3K4me3 135 
and the repressive epigenetic mark H3K27me3, which signifies genes that are silent but 136 
transcriptionally poised for activation [40, 41]. The bivalent histone modification patterns 137 
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disappear after cell differentiation, when most stemness genes are repressed in association with 138 
repressive epigenetic marks while specific differentiated genes become activated [40, 42]. At the 139 
same time, heterochromatin spreading takes place and chromatin plasticity is diminished [38, 140 
43]. 141 
Reprogramming, dedifferentiation and transdifferentiation. 142 
Unlike in lower vertebrates, reprogramming, dedifferentiation and transdifferentiation rarely 143 
occur naturally in mammals. However, under certain experimental conditions, differentiated cells 144 
can revert into a less differentiated state, in a dedifferentiation process induced by nuclear/cell 145 
reprogramming. Examples include the generation of induced pluripotent stem cells (iPSC) [44], 146 
or the creation of a totipotent embryo derived from somatic cell nuclear transfer (SCNT) [45]. 147 
Reprogramming also describes the conversion of one differentiated cell type into another, for 148 
instance of a B lymphocyte into a macrophage [46], or a fibroblast into a cardiac muscle cell 149 
[47], following the induced expression of defined transcription factors. Because these two 150 
examples of cell fate change may not involve a gain in differentiation potential, the term `lineage 151 
conversion' or `transdifferentiation' is currently used to describe these processes. Moreover, 152 
cellular dedifferentiation has also been implicated in cancer. As cancer can only be established 153 
from cells that have the potential to divide, and not terminally differentiated cells, one theory 154 
suggests that tumours may arise from the unrestrained growth of dedifferentiated cells that 155 
resemble embryonic or stem cells [48]. 156 
In molecular terms, cell reprogramming describes the molecular changes that cells undergo as 157 
their fate changes. Epigenetic reprogramming has been used to describe certain nuclear 158 
epigenetic changes that occur irrespective of changes to the differentiation state of cells, such as 159 
the DNA and histone methylation changes after fertilisation [49, 50], during germ cell 160 
maturation [51], dedifferentiation [37] and transdifferentiation [52]. 161 
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Epigenetic patterns can be inherited within cell lineages, as well as being dynamic during early 162 
development. Most somatic DNA and histone methylation modifications are erased during germ 163 
cell development [53, 54] and preimplantation stages [55], and are subsequently reinstated 164 
during pre and postimplantation [18, 32, 50]. It is thought that the erasure of ‘epigenetic 165 
memory’ is required for proper development, while incomplete and aberrant epigenetic 166 
reprogramming may cause developmental arrest and abnormalities [56-58].  167 
Manipulation of epigenetic profiles. 168 
Mechanisms of endogenous origin, as well as exogenous factors can be used to manipulate 169 
nuclear epigenetic profiles, and can in this way alter cell fate. Techniques include nuclear 170 
transfer [59], cell fusion [60], cell treatment with other cell extracts [61] or small molecules [62], 171 
and over expression of specific genes [63]. Such epigenetic reprogramming strategies may be 172 
useful for future therapies, for example in the treatment of cancers and mental retardation which 173 
have epigenetic abnormalities [64, 65]. Cell fate reprogramming strategies are already employed 174 
in disease modelling and have potential for regenerative medicine approaches aimed at tissue 175 
renewal [66]. Veterinary applications extend further into transgenic animal generation, drug 176 
development, and the preservation of biological diversity [67].  177 
Somatic cell nuclear transfer (SCNT) experiments in amphibians, and subsequently in sheep and 178 
other mammals, first demonstrated that it is possible to generate an adult cloned animal from a 179 
differentiated cell, albeit at low efficiency. [45, 68, 69]. Studies in different species using the 180 
nuclear transfer technique have shown that eggs or oocytes have the ability to erase somatic 181 
epigenetic patterns (epigenetic memory) of the donor nucleus and replace these with embryonic 182 
marks, leading to the development of pluripotent stem cells that are functionally equivalent to 183 
those derived from fertilized embryos. However, incomplete reprogramming by nuclear transfer 184 
may result in failure of full term development [58, 69-71].  185 
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Epigenetics in iPSC reprogramming. 186 
In a major advance demonstrating that cell reprogramming capability is not restricted to oocytes, 187 
ectopic expression or introduction of recombinant proteins of the pluripotency transcription 188 
factors (Oct4, Sox2, Klf4, Myc, Nanog, Lin28) was shown to be sufficient for reprogramming of 189 
a small proportion of somatic cells into a pluripotent state in mouse [44] and human cells [68]. 190 
These iPSCs are also in many respects similar to natural pluripotent embryonic stem cells 191 
(ESCs), such as the expression of certain stem cell genes and proteins, chromatin methylation 192 
patterns, doubling time, embryoid body formation, teratoma formation, and viable chimera 193 
formation, as well as potency and differentiability. Genomic mapping studies show that iPSC 194 
techniques can induce global epigenetic reprogramming of differentiated cells (fibroblasts) 195 
towards a pluripotent cell epigenome [63, 68]. The iPSC methodology permits the derivation of 196 
either patient-specific or disease-specific pluripotent cells. These cells can be used for drug 197 
screening, and as a model for the pathogenesis of degenerative diseases such as Alzheimer’s, 198 
Parkinson’s or multiple sclerosis, as well as having potential for cell therapy [72]. The study of 199 
iPS cells that are corrected for a gene mutation to rescue sickle cell anaemia and thalassemia in 200 
mouse models has demonstrated ‘proof of principle’ for the use of iPSC combined with gene 201 
therapy for disease treatment [73, 74]. Nevertheless, analysis of human iPSC lines suggests that 202 
variability in differentiation potential and the epigenetic control of cancer dedifferentiation 203 
during cell reprogramming need to be better understood prior to application in regenerative 204 
medicine [75, 76].  205 
Cell reprogramming in veterinary pre-clinical models and agriculture. 206 
Mouse models suggest treatment of a number of common degenerative diseases is possible using 207 
transplanted induced pluripotent stem cells. Mice lack physiological similarity with humans, 208 
however; while targeted gene mutation in mouse often fails to reproduce human phenotypes [77]. 209 
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Interest in the use of iPSCs in large animal pre-clinical models for disease modelling has ranged 210 
from rhesus monkey (pancreatic insulin-producing cells for diabetes), pig (rod photoreceptor 211 
cells for retinal disease; endothelial cells for cardiovascular disease), dog (endothelial cells), to 212 
macaque (dopaminergic neurons for Parkinsons disease). By filling the gaps between laboratory 213 
findings in the mouse and clinical trials in humans, domestic animal models are therefore 214 
invaluable for testing the safety and potential of iPSCs [67]. Interestingly, while somatic cell 215 
reprogramming to iPSCs in many species has relied on over-expression of the conserved 216 
Yamanaka set of transcription factors, additional steps are likely needed here to achieve a true 217 
pluripotent state with competence for germ-line transmission [67, 78]. Epigenetic modifications 218 
are evolutionary conserved but some variation exists between species in the modifying enzymes 219 
and binding protein homologues involved [9]. Overall, iPSC and ES cell technology have been 220 
mainly limited to rodents and humans. Instead, SCNT cell reprogramming technology has 221 
continued to deliver live births in a range of species including transgenic production in farm 222 
animals for potential agricultural applications [77]. 223 
Epigenetic inhibitors. 224 
In the last decade, a variety of small molecules have been created and discovered, some of which 225 
have the potential to alter epigenetic marks resulting in cell differentiation, transdifferentiation 226 
and dedifferentiation. Early examples include DNA demethylating agents such as 5-azacytidine 227 
(5-AzaC), which is a cytosine analogue that can cause extensive global DNA demethylation and 228 
reduce DNA methyltransferase activity in the cells [79, 80]. It was originally developed as an 229 
antitumor agent, and has been useful in the treatment of leukaemia and myelodysplastic 230 
syndrome [79, 81]. The effect of 5-AzaC is unpredictable, as it may cause dedifferentiation [82], 231 
differentiation [83] or transdifferentiation [84]. Other types of modifiers include histone 232 
deacetylase (HDAC) inhibitors such as valproic acid (VPA) and trichostatin (TSA). VPA has 233 
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been utilised for decades as a treatment for epilepsy, as a mood stabiliser and in migraine 234 
therapy, while TSA is currently applied as an anticancer medicine [85, 86]. It has been shown 235 
that both VPA and TSA can inhibit HDACs and then trigger active global demethylation of the 236 
mammalian epigenome, causing reprogramming of gene expression [87]. VPA and TSA induce 237 
dedifferentiation by enhancing epigenetic reprogramming in iPSC and SCNT technologies [88-238 
90]. Moreover, VPA and TSA can induce redifferentiation in cancer, causing growth inhibition 239 
and apoptosis [91, 92]. 240 
In addition, histone methylation inhibitors such as BIX-01294 (a diazepin-quinazolin-amine 241 
derivative) have been demonstrated to selectively impair G9a (Ehmt2) HMTs and levels of 242 
H3K9me2 [93]. A combination of BIX-01294 with defined factors (chromatin remodellers) 243 
could increase the cellular and epigenetic reprogramming rate of iPSC methodology [94]. 244 
Epigenetic modifier enzyme roles in differentiation in development and disease. 245 
Gene knockdown and knockout technologies in both in vivo and in vitro studies have revealed 246 
that mammalian development and differentiation requires both DNA/histone methylation (see 247 
table 1) and demethylation (see table 2). Most of the DNA and histone methyltransferases are 248 
important for normal embryonic development and differentiation. Conversely, most demethylase 249 
knockout embryos can survive until birth but cell differentiation is affected.  250 
Epigenetic modifiers are therefore essential and their defects are strongly linked to 251 
dedifferentiation towards stem cells or cancer (see table 1 and 2). The tables show that modifiers 252 
related to formation of heterochromatin, such as Suv39h, Suv420h, Dmnt1 and Dnmt3l, tend to 253 
act as repressors for dedifferentiation (table 1), whereas histone demethylases Jmjd1 and Jmjd2 254 
act as activators (table 2). H3K4 histone methyl transferases tend to activate cell reprogramming 255 
towards stem cells, but repress cancer (table 1). The important roles played in various 256 
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differentiation aspects identify these enzymes as potential drug targets for treating disease 257 
phenotypes and in regenerative reprogramming. 258 
Conclusion/Summary. 259 
In this review, we conclude that epigenetic marks are important for development, differentiation 260 
and that their dysregulation can cause dedifferentiation. Each cell phenotype has a unique 261 
epigenetic signature, which undergoes alteration when the cells are differentiated, 262 
transdifferentiated or dedifferentiated. Manipulation of epigenetic mechanisms can help control 263 
cell phenotypic outcomes in disease, and in this capacity can be useful for medicine and 264 
veterinary medicine, while animal production from reprogrammed somatic cells can find use in 265 
agriculture and animal conservation. The detailed information that is now available on the 266 
epigenomic maps (http://www.roadmapepigenomics.org/) from different adult and embryonic 267 
tissues, cross-referenced with disease states will provide the roadmap to these goals, as well as 268 
advancing our understanding of underlying epigenetic processes [95-97]. 269 
 270 
 271 
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Table 1 The importance of histone lysine methyltransferase and DNA methyltransferase for development, 941 
differentiation, cell reprogramming (SCNT and iPSC) and cancer. 942 
Site Enzyme 
Embryonic 
Lethality 
Abnormal 
differentiation Cell reprogramming Cancer Reference 
H3K4 
Setd1a/ 
Kmt2f 
Yes 
(E7.5) 
No - 
Activating 
(leukaemia) 
[98, 99] 
 
Setd1b/ 
Kmt2g 
Yes  
(E11.5) 
No - 
Repressive 
(squamous cell carcinoma) 
[98, 100]  
 
Mll/ 
Kmt2a 
Yes  
(E11.5) 
Yes 
(blood) 
Enhance 
Repressive 
(prostate carcinoma) 
[101-105] 
 
Kmt2b/ 
Mll4 
Yes  
(E10.5) 
Yes 
(heart) 
Enhance 
Repressive 
(squamous cell carcinoma) 
[103, 106-109] 
 
Mll3/ 
Kmt2c 
No 
Yes 
(blood) 
Enhance 
Repressive 
(myeloid leukemia) 
[103, 110-112]  
 
Kmt2d/ 
Mll2 
No 
Yes 
(heart) 
Enhance 
Repressive 
(lung cancer) 
[108, 109, 113, 
114] 
 
Kmt2e/ 
Mll5 
No 
Yes 
(heart) 
-  
Repressive 
(prostate carcinoma) 
[103, 115, 116] 
 
Setd7/ 
Kmt7 
No 
Yes 
(neuron) 
Inhibit 
Repressive 
(prostate cancer) 
[117-120] 
 
Smyd3/ 
Kmt3e 
- 
Yes 
(muscle) 
Enhance 
Activating 
(hepatocellular carcinomas) 
[121-123]  
H3K9 
Ehmt1/ 
Kmt1d 
Yes 
(E9.5) 
Yes 
(fat) 
Enhance 
Activating 
(parotid gland tumour) 
[124-127] 
 
Ehmt2/ 
Kmt1c 
Yes 
(E9.5) 
Yes 
(blood) 
Enhance 
Activating 
(lung cancer) 
[124, 126, 128-
130] 
 
Eset/ 
Kmt1e 
Yes 
(E8.5) 
Yes 
(bone) 
Enhance 
Activating 
(parotid gland tumour) 
[126, 127, 131, 
132] 
 
Suv39h1,2/ 
Kmt1a,b 
Yes 
(E14.5) 
Yes 
(muscle) 
Inhibit 
Repressive 
(alveolar rhabdomyosarcoma) 
[126, 133-136] 
 
Prdm2/ 
Kmt8/ 
No 
Yes 
(blood) 
- 
Repressive 
(B-cell lymphoma) 
[137, 138] 
 
Setdb2/ 
Kmt1f/ 
- - Enhance - 
[123] 
H3K27 
Ezh2/ 
Kmt6a 
Yes 
(E6.5) 
Yes 
(neuron) 
Enhance 
Activating 
(prostate cancer) 
[126, 139-141] 
 
Ezh1/ 
Kmt6b 
No 
Yes 
(skin) 
- - [142, 143] 
H4K20 
Suv420h1,2/ 
/Kmt5b,5c 
Yes 
(E18) 
Yes 
(neuron) 
Inhibit 
Repressive 
(skin cancer)  
[144-147] 
 
Setd8/ 
Kmt5a 
Yes 
(E2) 
Yes 
(skin) 
- 
Activating 
(bladder cancer) 
[148-150] 
H3K36 
Nsd1/ 
Kmt3b 
Yes 
(E10.5) 
Yes 
(blood) 
Enhance 
Activating 
(leukaemia) 
[151-154] 
 
Setd2/ 
Kmt3a 
Yes 
(E11.5) 
Yes 
(endoderm) 
- 
Activating 
(breast cancer) 
[155-157] 
 
Whsc1/ 
Nsd2 
No 
Yes 
(bone) 
Enhance 
Activating 
(prostate cancer) 
[123, 158-160] 
 
Smyd2/ 
Kmt3c 
No 
Yes 
(endoderm) 
- 
Activating 
(squamous cell carcinoma) 
[161-163] 
 
Setmar/ 
Metnase 
No - - 
Activating 
(leukaemia) 
[164, 165] 
 
Ash1l/ 
Kmt2h 
No 
Yes 
(endoderm) 
- - 
[166] 
H3K79 
Dot1L/ 
Kmt4 
Yes 
(E9.5) 
Yes 
(ectoderm) 
Inhibit 
Repressive 
(leukaemia) 
[126, 127, 167-
169] 
DNA Dnmt1 
Yes 
(E9.5) 
Yes 
(neuron) 
Inhibit 
Repressive 
(colorectal carcinoma) 
[126, 170-172] 
 Dnmt3L 
Yes 
(E15.5) 
Yes 
(germ cell) 
Enhance 
Activating 
(squamous cell carcinoma) 
[173-176] 
 Dnmt3a No 
Yes 
(blood) 
Inhibit 
Repressive 
(breast cancer) 
[126, 177-179] 
 Dnmt3b 
Yes 
(E15.5) 
Yes 
(neuron) 
- 
Repressive 
(colorectal carcinoma) 
[172, 177, 180] 
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Table 2. The importance of histone histone (lysine) demethylase and DNA demethylases for development, 945 
differentiation, cell reprogramming (SCNT and iPSC), and cancer. 946 
Site Enzyme 
Embryonic 
lethality 
Abnormal 
differentiation 
Cell 
reprogramming Cancer 
Reference 
DNA Tet1 No 
Yes 
(neuron) 
Enhance 
Repressive 
(prostate cancer) 
[181-184] 
 Tet2 No 
Yes 
(blood) 
Enhance Repressive (leukaemia) 
[185-189] 
 Tet3 No  
Yes 
(neuron) 
Enhance 
Repressive  
(breast cancer) 
[190-192] 
 Tet1-3 No  
Yes 
(three germ layers) 
- - [182, 183] 
H3K9 
H3K4 
H4K20
H3K27 
Phf8/ 
Jhdm1f 
- 
Yes 
(neuron) 
- 
Activating 
(prostate cancer) 
[193, 194] 
H3K4 
H3K27 
Nsd3/ 
Whsc1l1 
- - - 
Repressive 
(breast cancer) 
[195] 
H3K36 
Kdm2a/ 
Jhdm1a 
- 
Yes 
(fat) 
Enhance 
Activating 
(lung tumour) 
[196-198] 
 
Jmjd5/ 
Kdm8 
Yes 
(E11) 
Yes 
(bone) 
- 
Activating 
(breast cancer) 
[199-201] 
H3K4 
H3K36 
C14orf169/
No66 
- 
Yes 
(three germ layers) 
- 
Activating 
(lung cancer) 
[202, 203] 
 
Kdm2b/ 
Jhdm1b 
Yes 
(E19) 
Yes 
(neuron) 
Enhance 
Activating 
(pancreatic cancer) 
[204-206] 
 
Kdm1a/ 
Lsd1 
Yes 
(E10.5) 
Yes 
(three germ layers) 
Inhibit 
Activating 
(breast cancer) 
[207-210] 
H3K4 Prdm9 No No - 
Activating 
(ovarian cancer) 
[211-213] 
 
Kdm5a/ 
Jarid1a 
No 
Yes 
(pancreas) 
Enhance 
Activating 
(leukaemia) 
[214-217] 
 
Kdm5b/ 
Jarid1b 
No 
Yes 
(blood) 
Inhibit 
Activating 
(prostate cancer) 
[194, 218-221] 
 
Kdm5c/ 
Jarid1c 
Yes 
(E15.5) 
Yes 
(neuron) 
- 
Activating 
(prostate cancer) 
[222-224] 
 
Kdm5d/ 
Jarid1d 
- No - 
Repressive 
(prostate cancer) 
[223, 225] 
H3K9 
Kdm3a/ 
Jmjd1a 
Yes 
Yes 
(endoderm) 
Enhance 
Activating 
(prostate cancer) 
[136, 194, 226-230] 
 
Kdm3b/ 
Jmjd1b 
- - Enhance 
Activating 
(prostate cancer) 
[136, 194] 
 
Kdm4a/ 
Jmjd2a 
Yes 
Yes 
(heart) 
No effect 
Activating 
(prostate cancer) 
[136, 194, 230, 231] 
 
Kdm4b/ 
Jmjd2b 
- 
Yes 
(bone) 
Enhance 
Activating 
(colorectal cancer) 
[136, 232, 233] 
 
Kdm4c/ 
Jmjd2c 
Yes 
(E2) 
No Enhance 
Activating 
(breast cancer) 
[136, 230, 234-236] 
 
Kdm4d/ 
Jmjd2d 
No No No effect 
Activating 
(colorectal cancer) 
[136, 237, 238] 
 
Kdm1b/ 
Lsd2 
No No Inhibit 
Activating 
(prostate cancer) 
[239, 240] 
H3K9 
H3K27 
Kdm7a/ 
Jhdm1d 
- 
Yes 
(neuron) 
- 
Repressive 
(uterine cancer) 
[241, 242] 
H3K27 
Kdm6a/ 
Utx 
Yes 
(E12.5) 
Yes 
(mesoderm) 
Enhance 
Repressive 
(myeloma) 
[217, 243-245] 
 
Kdm6b/ 
Jmjd3 
No 
Yes 
(bone) 
Enhance 
Repressive 
(Glioblastoma) 
[217, 232, 246-248] 
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